Form 4: Roivant Sciences CEO Matthew Gline Sells Shares to Cover Tax Obligations

Roivant Sciences CEO Matthew Gline sold 10,945 common shares to cover tax obligations related to the vesting of restricted stock units.

Summary

• Matthew Gline, CEO of Roivant Sciences Ltd., sold 10,945 common shares on November 20, 2024.
• The sale was executed at a price of $11.49 per share.
• This transaction was a 'net settlement' by the company to cover tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs).
• Following the transaction, Gline directly owns 17,350,114 common shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for companies to withhold shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• The practice of selling shares to cover tax obligations on vesting RSUs is standard across publicly traded companies.
• Many companies use a 'net settlement' approach, where the company withholds a portion of the shares to cover taxes, as seen in this transaction.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Roivant Sciences, Matthew Gline, share sale, insider trading, Form 4, restricted stock units, tax obligations, equity compensation